In the last 12 months, Teva of Israel's share price has climbed almost 100% to a peak of around $48.50. But in recent weeks the stock has fallen over 30% to $34.50.
The most recent sharp fall, almost 9%, occurred on the same day that US generics company Ivax warned that second-quarter results are to be significantly affected by the continuing price erosion in the US generic drugs market. Following the acquisition of Biocraft Laboratories, Teva is considered to be the second largest generics firm in the USA.
Following the comments from Ivax, William Fletcher, president of Lemmon, Teva's US generics unit, stated: "while it is too early to comment on Lemmon's results for the second quarter, Lemmon's sales (excluding Biocraft, which will be consolidated for the first time this quarter) are expected to be ahead of both the first quarter of 1996 and the comparable quarter last year."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze